CD274 and non-small cell lung carcinoma: In this pooled analysis, pembrolizumab monotherapy improved clinical outcomes versus chemotherapy in patients with PD-L1–positive advanced or metastatic NSCLC, irrespective of the presence of treated, stable brain metastases at baseline.